COVID-19 “Liquid Biopsy” Could Offer Monitoring, Prognostic Tool
نویسندگان
چکیده
منابع مشابه
Geographic Information System (GIS): A Reliable Tool for Monitoring COVID-19 in Iran and the World
This article has no abstract.
متن کاملLiquid biopsy for cancer screening, patient stratification and monitoring
Molecular characterization of a patient’s tumor to guide treatment decisions is increasingly being applied in clinical care and can have a significant impact on disease outcome. These molecular analyses, including mutation characterization, are typically performed on tissue acquired through a biopsy at diagnosis. However, tumors are highly heterogeneous and sampling in its entirety is challengi...
متن کاملORF8 ∆382 Mutation: A Possible Viral Prognostic Biomarker for the Severity of the COVID-19
Since the initial onset of the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic from Wuhan, China in December 2019, the virus is now spread all around the world, and the disease is named COVID-19. Based on the WHO report on April 18, 2021, there are now more than 140 million confirmed cases and three millions deaths due to this disease[1]. The virus pathogenesis, cl...
متن کاملLiquid Biopsy in Liquid Tumors
The availability of a minimally invasive patient simple, capable of providing tumor information, represents a valuable clinical tool. The liquid biopsy has the potential to achieve this need. Circulating cell free DNA (ccfDNA), other circulating nucleic acids such as microRNA and circulating tumor cells (CTCs), can be obtained from a peripheral blood sample. Liquid biopsy has been particularly ...
متن کاملLiquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
PURPOSE OF REVIEW The aim of this review is to highlight the recent advances (in the past 12 months) concerning circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in oncology. RECENT FINDINGS The value of CTCs as a prognostic biomarker is now well validated in breast, colon, and prostate cancer, but no trial has yet demonstrated that modifying treatment according to CTCs is supe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA
سال: 2021
ISSN: ['0098-7484', '1538-3598']
DOI: https://doi.org/10.1001/jama.2021.2496